Country intelligence
Deals, market moves, science and policy across the platform tagged to France.
Europe's largest untapped medical market — moving from trial to a permanent framework by 2026.
Market sizing, forecasts, pricing and patient data are available to Prohibition Partners subscribers. View on Prohibition Partners →
In March 2025 France notified the European Commission of its intention to legalise medical cannabis authorisation and production; once the TRIS procedure concludes, the HAS will rule on reimbursement. The new framework may allow granulated flower — consumed via a CE-certified vaporiser, not smoked — and approve products through temporary use authorisations overseen by the ANSM.
Only trained, certified physicians will prescribe, with training programmes to be created. Cannabis remains a last-resort treatment requiring intolerance or failure of other therapies. Approved indications include neuropathic pain, drug-resistant epilepsy, MS-related spasticity, chemotherapy side-effects and palliative care.
The HAS has yet to determine how medical cannabis will be reimbursed under public health insurance.
Domestic cultivation and manufacture will be permitted under the new system, restricted to indoor growing and requiring a binding contract with an authorised establishment before any cannabis is grown.
